Joseph Shulman - Feb 9, 2024 Form 4/A - Amendment Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Technical Officer
Signature
/s/ Stephen Vander Stoep as Attorney-in-Fact for Joseph Shulman
Stock symbol
RYTM
Transactions as of
Feb 9, 2024
Transactions value $
$1,420,540
Form type
4/A - Amendment
Date filed
11/13/2024, 09:01 PM
Date Of Original Report
Feb 13, 2024
Previous filing
Feb 5, 2024
Next filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $1.39M +65.2K +1243.8% $21.38 70.4K Feb 9, 2024 Direct F1
transaction RYTM Common Stock Options Exercise $27.1K +3.99K +5.66% $6.80 74.4K Feb 9, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (right to buy) Options Exercise $0 -65.2K -85.98% $0.00 10.6K Feb 9, 2024 Common Stock 65.2K $21.38 Direct F1, F2
transaction RYTM Stock Option (right to buy) Options Exercise $0 -3.99K -11.11% $0.00 31.9K Feb 9, 2024 Common Stock 3.99K $6.80 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This amendment is being filed to correct the number of options exercised in row two of each of Table I and Table II in the originally filed Form 4 on February 13, 2024; and to report the exercise of the options in row two of each of Table I and Table II in this amended Form 4. The originally filed Form 4 reported 69,190 options exercised in row two of each of Table 1 and Table II which should have been 69,160, the total amount actually exercised.
F2 The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.
F3 The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Remarks:

Exhibit 24